Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flucloxacillin influence on CYP and UGT substrate drug plasma concentrations
NL-OMON56926Terminated
- Sponsor
- HagaZiekenhuis
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of flucloxacillin in Staphylococcus aureus infection and Infection (5 arms), sponsored by HagaZiekenhuis. Primary endpoint: Difference in AUC of each substrate drug. Started Nov 2024; status: terminated.
02
Drugs
flucloxacillin
03
Conditions
Staphylococcus aureus infectionInfection
Beyond the preview
Go deeper on NL-OMON56926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56926.